when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Keytruda · news · pharmadog

← back to Keytruda

News mentioning Keytruda

171 stories

21dHighlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancerfiercebiotech

22dMerck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitorbiospace

22dMerck, Daiichi end plans to seek speedy approval of lung cancer ADCbiopharma dive

23d6 immunology targets to sustain a mammoth I&I marketbiospace

25dNovo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s databiopharma dive

26dMerck reveals study success, and possible safety worries, for eye drug hopefulbiopharma dive

26dMerck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emergebiospace

26dMerck’s return to ophthalmology snags first successendpoints

26dMerck sees pivotal victory for $3B eye disease prospectfiercebiotech

Sep 15, 26WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlightbiopharma dive

Sep 14, 26Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study resultsbiopharma dive

Sep 14, 26Summit, BioNTech, more headline WCLC with next-gen lung cancer drugsbiospace

Sep 14, 265 drugmakers chasing Merck and Moderna in the cancer vaccine racebiospace

Sep 14, 26After a brief storm of political headwinds, mRNA is back with strong momentumbiospace

Sep 13, 26Akeso details survival win for its PD-1xVEGF drug versus Keytrudaendpoints

Sep 11, 26mRNA cancer vaccines’ biggest barriers to marketbiopharma dive

Sep 10, 26The signal that changes everything: understanding MRD in oncology drug developmentfiercebiotech

Sep 10, 26Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'biospace

Sep 9, 26Solstice rises with $225M to develop next-gen CTLA-4 drug from Chinabiospace

Sep 9, 26A new immuno-oncology play raises $225M for a next-generation drugbiopharma dive

Sep 9, 26Caspian launches with $50M, Lilly support to advance disease-modifying diabetes betbiospace

Sep 9, 26Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2fiercebiotech

Sep 8, 26Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapybiopharma dive

Sep 8, 26Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancerbiospace

Sep 8, 26Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’biospace

Sep 8, 26Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durabilityfiercebiotech

Sep 3, 26Merck's top dealmaker signals more M&A as Keytruda's patent cliff nearsendpoints

Sep 3, 26Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—againbiospace

Sep 3, 26Akeso, Summit cancer drug confirms lung cancer survival benefitbiopharma dive

Sep 2, 26Novartis inks $3.2B subcutaneous drug delivery deal with Alteogenfiercebiotech

← prevpage 2 of 6next →